Evidence map›Paper›PMID 29671245›Full record

ArticleInternational journal of hematology2018

Severe graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with residual mogamulizumab concentration.

Hiroki Hosoi, Toshiki Mushino, Akinori Nishikawa, Hisako Hashimoto, Shogo Murata, Kazuo Hatanaka, Shinobu Tamura, Nobuyuki Hanaoka, Norio Shimizu, Takashi Sonoki

Abstract readCase ReportsLetter
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.International journal of molecular sciences · 2024
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hiroki HosoiHematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8510, Japan.
Toshiki MushinoHematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8510, Japan.
Akinori NishikawaHematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8510, Japan.
Hisako HashimotoDepartment of Cell Therapy, Institute of Biomedical Research and Innovation, 2-2, Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan.
Shogo MurataHematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8510, Japan.
Kazuo HatanakaHematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8510, Japan.
Shinobu TamuraHematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8510, Japan.
Nobuyuki HanaokaHematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8510, Japan.
Norio ShimizuDivision of Advanced Biomedical Engineering Research, Center for Stem Cell and Regenerative Medicine, Institute of Research, Tokyo Medical and Dental University, Tokyo, Japan.
Takashi SonokiHematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8510, Japan. sonoki@wakayama-med.ac.jp.ORCID 0000-0002-0211-3311

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedGraft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemia-Lymphoma, Adult T-CellAllograftsHumansMaleMiddle AgedAntibodies, Monoclonal, Humanizedmogamulizumab

Identifiers

PMID29671245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.